Version 1
: Received: 7 June 2024 / Approved: 7 June 2024 / Online: 10 June 2024 (06:46:32 CEST)
How to cite:
Raghav, A.; Jeong, G. B. Phase I–IV Drug Trials on Hepatocellular Carcinoma in an Asian Population: A Systematic Review of Ten Years Studies. Preprints2024, 2024060517. https://doi.org/10.20944/preprints202406.0517.v1
Raghav, A.; Jeong, G. B. Phase I–IV Drug Trials on Hepatocellular Carcinoma in an Asian Population: A Systematic Review of Ten Years Studies. Preprints 2024, 2024060517. https://doi.org/10.20944/preprints202406.0517.v1
Raghav, A.; Jeong, G. B. Phase I–IV Drug Trials on Hepatocellular Carcinoma in an Asian Population: A Systematic Review of Ten Years Studies. Preprints2024, 2024060517. https://doi.org/10.20944/preprints202406.0517.v1
APA Style
Raghav, A., & Jeong, G. B. (2024). Phase I–IV Drug Trials on Hepatocellular Carcinoma in an Asian Population: A Systematic Review of Ten Years Studies. Preprints. https://doi.org/10.20944/preprints202406.0517.v1
Chicago/Turabian Style
Raghav, A. and Goo Bo Jeong. 2024 "Phase I–IV Drug Trials on Hepatocellular Carcinoma in an Asian Population: A Systematic Review of Ten Years Studies" Preprints. https://doi.org/10.20944/preprints202406.0517.v1
Abstract
Background: Despite advances in the treatment of hepatocellular carcinoma (HCC) over the last few decades, treatment opportunities for patients with HCC remain limited. HCC is the most common form of liver cancer, accounting for approximately 90% of all cases worldwide. Moreover, apart from the current pharmacological interventions, hepatic resection and liver transplantation are the mainstay curative approaches for patients with HCC.
Methods: This systematic review included phase I, II, III, and IV clinical trials (CTs) and randomized controlled trials (RCTs) on current treatments for patients with HCC in an Asian population (2013–2023). A total of 427 articles were screened, and 184 non-duplicate publications were identified. After screening titles and abstracts, 96 publications were excluded, and another 28 were excluded after full-text screening. The remaining 60 eligible RCTs/CTs were finally included.
Results: Sixty clinical trials fulfilled our inclusion criteria and screened 36 drugs as monotherapy or combination therapy for HCC. Most studies used sorafenib alone or in combination with any of the treatment regimens. Lenvatinib or atezolizumab with bevacizumab was used for HCC after initial sorafenib treatment. Eighteen studies compared the efficacy of sorafenib with that of other drugs, including lenvatinib, cabozantinib, tepotinib, tigatuzumab, linifanib, erlotinib, resminostat, brivanib, tislelizumab, selumetinib, and refametinib.
Conclusion: This study provides comprehensive insights into effective treatment interventions for HCC in Asian populations. The overall assessment indicated that sorafenib alone or in combination with atezolizumab and bevacizumab has been the first treatment choice in the past decade to achieve better outcomes in patients with HCC in an Asian population
Keywords
Hepatocellular carcinoma; Systematic; Asian Population; Treatment
Subject
Medicine and Pharmacology, Gastroenterology and Hepatology
Copyright:
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
